Company Overview of Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is ...
430 East 29th Street
New York, NY 10016
Key Executives for Intra-Cellular Therapies, Inc.
Co-Founder, Chairman, Chief Executive Officer and President
Total Annual Compensation: $1.1M
Chief Financial Officer, Vice President of Finance, Treasurer and Assistant Secretary
Total Annual Compensation: $560.0K
Senior Vice President, General Counsel, Corporate Compliance Officer and Secretary
Total Annual Compensation: $618.8K
Chief Scientific Officer and Senior Vice President
Total Annual Compensation: $560.0K
Senior Vice President of Clinical Development
Total Annual Compensation: $525.0K
Compensation as of Fiscal Year 2016.
Intra-Cellular Therapies, Inc. Key Developments
Khang & Khang LLP Announces Securities Class Action Lawsuit Against Intra-Cellular Therapies, Inc
May 13 17
Khang & Khang LLP announced the filing of a class action lawsuit against Intra-Cellular Therapies, Inc. Investors who purchased or otherwise acquired shares between August 12, 2014 and April 28, 2017, inclusive (the class Period), are encouraged to contact the Firm in advance of the July 11, 2017 lead plaintiff motion deadline. According to the Complaint, throughout the Class Period, Intra-Cellular made false and/or misleading statements and/or failed to disclose: that findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; that these findings posed an additional safety concern regarding lumateperone; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company's CEO Sharon Mates touted the efficacy and safety of ITI-007 for the treatment of schizophrenia. On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients. Upon release of this news, Intra-Cellular's stock price fell materially, which harmed investors according to the Complaint.
Rosen Law Firm Continues to Investigate Securities Claims against Intra-Cellular Therapies, Inc
May 11 17
Rosen Law Firm announced it is continuing to investigate potential securities claims on behalf of shareholders of Intra-Cellular Therapies, Inc. resulting from allegations that Intra-Cellular Therapies may have issued materially misleading business information to the investing public. Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Intra-Cellular Therapies investors.
Intra-Cellular Therapies, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017
May 10 17
Intra-Cellular Therapies, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, loss from operations was $27,754,157,000 compared to $28,497,853,000 a year ago. Net loss was $26,933,582,000 or $0.62 per basic and diluted share compared to $27,841,449,000 or $0.64 per basic and diluted share a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|